Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-11-20
2007-11-20
O'Hara, Eileen B. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C536S023100
Reexamination Certificate
active
10863880
ABSTRACT:
The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure.
REFERENCES:
patent: 6770742 (2004-08-01), Ullrich et al.
patent: WO 92/13948 (1992-08-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 98/24432 (1998-06-01), None
patent: WO 98/50356 (1998-11-01), None
Ratisoontorn et al., Connect. Tissue Res., 2003, vol. 44, Suppl. 1, pp. 292-297.
Friesel et al., Development, 1992, vol. 116:1051-1058.
Buchdunger et al.,Clinical Cancer Research, 1 (8), 813-821 (1995).
CALBIOCHEM® Signal Transduction Catalog & Technical Resource, p. 259 (1998).
Ciardello et al.,Clinical Cancer Research, 1 (2), 161-167 (1995).
Coll-Fresno et al.,Oncogene, 14 (2), 243-247 (1997).
Dinney et al.,Clinical Cancer Research, 3 (2), 161-168 (1997).
Han et al.,Oncology Research, 9 (11-12), 581-587 (1997).
Mohammadi et al.,Science, 276 (5314), 955-960 (May 9, 1997).
Neilson et al.,The Journal of Biological Chemistry, 271 (40), 25049-25057 (1996).
Normanno et al.,Clinical Cancer Research, 2 (3), 601-609 (1996).
Partanen et al.,EMBO Journal, 10 (6), 1347-1354 (1991).
Rubin Grandis et al.,Oncogene, 15 (4), 409-416 (1997).
Showalter et al.,Pharmacol. Ther., 76 (1-3), 55-71 (1997).
Uehara,Japanese Journal of Cancer&Chemotherapy, 24 (11), 1536-1540 (1997).
Munoz et al., “Effect of Mutation of Cytoplasmic Receptor Domain and of Genistein on Transport of Acidic Fibroblast Growth Factor into Cells,”Oncogene, 15: 525-536 (1997).
Bange Johannes
Knyazev Pjotr
Ullrich Axel
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
O'Hara Eileen B.
Xie Xiaozhen
LandOfFree
Use of inhibitors for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858582